688062 迈威生物
2025/06 - 中期2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)-46.194-50.278-34.542-42.206-62.027
总资产报酬率 ROA (%)-12.610-23.914-23.217-30.741-47.591
投入资产回报率 ROIC (%)-14.430-27.048-25.631-33.308-52.427

边际利润分析
销售毛利率 (%)78.70085.50898.92899.74581.022
营业利润率 (%)-546.079-522.310-823.385-3,455.471-4,762.015
息税前利润/营业总收入 (%)-509.967-505.925-851.640-3,580.798-4,740.602
净利润/营业总收入 (%)-545.868-523.854-828.261-3,455.423-4,762.038

收益指标分析
经营活动净收益/利润总额(%)103.325101.19899.315100.790103.896
价值变动净收益/利润总额(%)0.5160.3560.445-0.187-0.499
营业外收支净额/利润总额(%)-0.0480.3810.257-0.0010.000

偿债能力分析
流动比率 (X)0.9031.1062.5086.2410.905
速动比率 (X)0.8010.9692.3136.0630.757
资产负债率 (%)77.54163.61242.24024.00436.774
带息债务/全部投入资本 (%)67.54154.50629.07314.78015.183
股东权益/带息债务 (%)31.74575.237228.261549.751472.519
股东权益/负债合计 (%)23.61057.685137.299317.053172.300
利息保障倍数 (X)-14.226-27.52232.58528.561-221.160

营运能力分析
应收账款周转天数 (天)84.76750.32324.7611.3984.058
存货周转天数 (天)1,764.7722,306.48831,319.667303,610.3544,377.963